Normal striatal d2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep

Nuclear Medicine Communications

Volumn 25, Issue 1, 2004, Pages 55-60

  Tribl, G G ^a   Asenbaum, S ^a   Happe, S ^a   Bonelli, R M ^a   Zeitlhofer, J ^a   Auff, E ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

D2 dopamine receptor binding; I IBZM; Restless legs syndrome; Single photon emission computerized tomography (SPECT); Sleep disorders

Indexed keywords

3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; ANTICONVULSIVE AGENT; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; PYRROLIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE;

ADULT; AGE; AGED; AGING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HOSPITALIZATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; PARASOMNIA; RESTLESS LEGS SYNDROME; SCINTISCANNING; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DOPAMINE RECEPTOR BLOCKING; EVALUATION; FRONTAL CORTEX; INTERMETHOD COMPARISON; LEG MOVEMENT; POLYSOMNOGRAPHY; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTICONVULSANTS; BENZAMIDES; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NOCTURNAL MYOCLONUS SYNDROME; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX;

EID: 0842312542     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200401000-00008     Document Type: Article

References (39)

1. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160: 2137-2141.
2. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997; 12: 61-65.
3. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: An association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001; 16: 1159-1163.
4. Ulfberg J, Nystrom B, Carter N, Edling C. Restless legs syndrome among working-aged women. Eur Neurol 2001; 46: 17-19.
5. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995; 10: 634-642.
6. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001; 18: 128-147.
7. Trenkwalder C, Stiasny K, Pollmacher T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995; 18: 681-688.
8. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999; 22: 970-999.
9. Montplaisir J, Lorrain D, Godbout R. Restless legs syndrome and periodic leg movements in sleep: the primary role of dopaminergic mechanism. Eur Neurol 1991; 31: 41-43.
10. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
11. Kraus T, Schuld A, Pollmacher T. Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol 1999; 19: 478-479.
12. Trenkwalder C, Walters AS, Hening WA, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999; 14: 141-145.
13. 11C-raclopride PET studies. Neurology 1999; 52: 932-937.
14. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54: 502-504.
15. Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001; 57: 1307-1309.
16. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002; 249: 164-170.
17. Staedt J, Stoppe G, Kogler A, et al. Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus). J Neural Transm Gen Sect 1993; 93: 71-74.
18. Staedt J, Stoppe G, Kogler A, et al. Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci 1995; 245: 8-10.
19. von Scheele C. Levodopa in restless legs. Lancet 1986; 2: 426-427.
20. Recording and scoring leg movements. The Atlas Task Force. Sleep 1993; 16: 748-759.
21. Buysse DJ, Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
22. Hening WA, Walters AS, Rosen R, LeBroca C, Hirsch L, Dhar A, Members I. The international RLS study group rating scale: A reliable and valid instrument for assessing severity of the restless legs syndrome. Neurology 2001; 56: A4.
23. Brucke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11: 220-228.
24. Wong DF, Wagner Jr HN, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226: 1393-1396.
25. Staedt J, Stoppe G, Kogler A, et al. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS). J Neural Transm Gen Sect 1995; 99: 187-193.
26. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971; 46: 231-239.
27. Zappia M, Oliveri RL, Bosco D, et al. The long-duration response to L-dopa in the treatment of early PD. Neurology 2000; 54: 1910-1915.
28. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000; 39: 243-254.
29. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996; 30: 463-481.
30. Bara-Jimenez W, Aksu M, Graham B, Sato S, Hallett M. Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 2000; 54: 1609-1616.
31. de Mello MT, Poyares DL, Tufik S. Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions. Spinal Cord 1999; 37: 634-637.
32. Jankowska E, Jukes MG, Lund S, Lundberg A. The effect of DOPA on the spinal cord. 6. Half-centre organization of interneurones transmitting effects from the flexor reflex afferents. Acta Physiol Scand 1967; 70: 389-402.
33. Abdelmelek H, Cottet-Emard JM, Pequignot JM, Barre H. Spinal cord monoaminergic system response to age and cold-acclimatization in muscovy duckling. J Neural Transm 2000; 107: 1175-1185.
34. Skagerberg G, Bjorklund A, Lindvall O, Schmidt RH. Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res Bull 1982; 9: 237-244.
35. Lindvall O, Bjorklund A, Skagerberg G. Dopamine-containing neurons in the spinal cord: anatomy and some functional aspects. Ann Neurol 1983; 14: 255-260.
36. Fleetwood-Walker SM, Coote JH. Contribution of noradrenaline-, dopamine- and adrenaline-containing axons to the innervation of different regions of the spinal cord of the cat. Brain Res 1981; 206: 95-106.
37. Weil-Fugazza J, Godefroy F. Further evidence for the involvement of the diencephalo-dopaminergic system in pain modulation: a neurochemical study on the effect of morphine in the arthritic rat. Int J Tissue React 1991; 13: 305-310.
38. Weil-Fugazza J, Godefroy F. Dorsal and ventral dopaminergic innervation of the spinal cord: functional implications. Brain Res Bull 1993; 30: 319-324.
39. Commissiong JW, Sedgwick EM. Letter: Dopamine and noradrenaline in human spinal cord. Lancet 1975; 1: 347.